Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTOF), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd (CYTOF) is a biotechnology company focused on peptide-based nanoparticle technologies for nucleic acid and RNA delivery. Company news and press releases highlight developments around its xPhore™ platform, internal RNA programs, and legacy assets in allergy and inner ear disorders.
Readers following CYTOF news can expect updates on RNA and DNA delivery technology, including new data from in vitro and in vivo studies, expansion of the xPhore platform to modalities such as siRNA, mRNA, circular RNA, and DNA, and the introduction of sub-platforms like OligoPhore™, SemaPhore™, CycloPhore™, and GenePhore™. Altamira also reports on collaboration agreements with biotech and pharma partners who evaluate these platforms for applications such as mRNA vaccines, radiopharmaceutical cancer therapies, and circular RNA-based drugs.
Another recurring theme in Altamira’s news is progress with its legacy portfolio. This includes regulatory and commercial milestones for Bentrio®, an over-the-counter, drug-free nasal spray for allergic rhinitis owned by its associate Altamira Medica AG. Recent announcements have covered certification of Bentrio under the EU Medical Device Regulation, marketing approval in Mainland China, and patent protection steps in the United States. News items also address intellectual property developments for AM-125, an intranasal betahistine program for acute vestibular syndrome.
Altamira’s releases further provide business updates and financial results, including information on operating expenses, research and development focus, and plans to partially spin off its RNA delivery subsidiary to private equity investors. Investors and observers who monitor CYTOF news can use this page to track technology progress, partnering activity, regulatory milestones, and strategic corporate moves over time.
Altamira Therapeutics (OTCQB:CYTOF) has entered into a collaboration agreement with an undisclosed company to evaluate its CycloPhore™ platform for circular RNA payload delivery. The partnership involves testing CycloPhore nanoparticles both in vitro and in vivo, with the partner having an option to negotiate a license agreement for developing and commercializing circRNA nanoparticles with their proprietary RNA payload.
The collaboration marks the first partnership for Altamira's recently launched CycloPhore platform, specifically designed for circular RNA delivery. According to COO Covadonga Pañeda, circular mRNA could enable lower dosing and less frequent administrations compared to linear mRNA, representing a promising approach in RNA drug development.
Altamira Therapeutics reported its full year 2024 financial results, highlighting significant progress in its RNA delivery business. The company's xPhore platform demonstrated successful testing with circular RNA, showing higher protein expression compared to linear mRNA. Operating loss from continuing operations increased slightly to $6.9 million, while cash used in operations decreased by more than half to $6.1 million.
Key developments include:
- Plans to partially spin off RNA delivery business to private equity investors
- Successful testing of xPhore platform with circular RNA
- New collaborations with Univercells Group for mRNA vaccines and an undisclosed radiopharmaceutical partner
- Year-end cash position of $1.0 million, up from $0.7 million in 2023
- Shareholders' equity of $6.6 million, down from $7.7 million in 2023
The company expects to sign at least two more partnerships in 2025 and plans to reduce operating expenses following the planned partial spin-off of its ATAG subsidiary.
Altamira Therapeutics (OTCQB: CYTOF), a company focused on RNA delivery technology development for targets beyond the liver, has scheduled its Full Year 2024 Financial Results and Business Update Call for April 30, 2025, at 8:00 am ET.
The presentation will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The call will be conducted in listen-only mode, with replay access available through the webcast link after the live event.
Altamira Therapeutics (OTCQB:CYTOF) has received a Notice of Allowance from the USPTO for a patent application (#17/466,142) covering the composition of Bentrio®, their nasal spray for allergic rhinitis treatment and prevention. The patent, with a priority date of September 8, 2020, will protect Bentrio's proprietary formulation in the USA, which represents the largest market for OTC allergic rhinitis products.
The drug-free and preservative-free nasal spray has shown significant effectiveness in relieving classic nasal symptoms of allergic rhinitis, including congestion, sneezing, itching, rhinorrhea, and ocular symptoms. The company plans to expand product availability globally through partnerships in the consumer health sector.
Altamira Therapeutics (OTCQB:CYTOF) has entered into a collaboration agreement with an unnamed radiopharmaceutical company to evaluate its RNA delivery platform for radiopharmaceutical targeting in cancer treatment. The collaboration will test RNA nanoparticles in conjunction with the partner's proprietary radiopharmaceuticals both in vitro and in vivo.
Upon successful completion of experiments, the partner will have the option to negotiate a license and supply agreement for developing and commercializing the RNA nanoparticles in cancer treatment. The global radiopharmaceutical market reached $8.4 billion in 2024 and is projected to grow to $17.1 billion by 2033.
Radiopharmaceutical therapy utilizes small amounts of radioactive compounds that, when injected, travel through the bloodstream to bind to tumor-specific receptors for diagnosis and treatment of various diseases, particularly cancer.
Altamira Therapeutics (OTCQB:CYTOF) has successfully tested its nanoparticle-based delivery platform for circular mRNA, demonstrating higher protein expression compared to linear mRNA in vitro. The company has filed a provisional patent application with the USPTO and will offer the platform under the CycloPhore™ brand, alongside existing OligoPhore™ (siRNA) and SemaPhore™ (mRNA) solutions.
The circular mRNA technology offers enhanced protein expression and greater stability compared to linear mRNA, potentially enabling lower dosing and less frequent administrations for therapeutic indications and vaccines. This development further validates the versatility of Altamira's extrahepatic RNA delivery platform.